Insulin Pump Market Size & Share

1. The global insulin pump market is projected to grow from $6.08 billion in 2024 to $21.65 billion by 2032, with a compound annual growth rate (CAGR) of 17.2%. North America dominates the market with a 57.79% share in 2023. Key market developments include:  Tandem Diabetes Care's launch of Tandem Mobi, a compact automated insulin delivery system, in February 2024  FDA approval of Roche Diabetes' Accu-Chek Solo micropump in September 2023  FDA approval of Beta Bionics iLet ACE Pump for type 1 diabetes patients aged six and above in May 2023 Leading companies in the market include:  Medtronic (Ireland)  Tandem Diabetes Care (U.S.)  Ypsomed AG (Switzerland)  Insulet Corporation (U.S.)  F. Hoffmann-La Roche Ltd (Switzerland) Market growth is driven by:  Rising prevalence of diabetes worldwide  Increasing adoption of insulin pumps for type 2 diabetes  Development of AI-powered diabetes management devices  Favorable reimbursement policies in developed countries Key challenges include the high cost of insulin pumps, which limits adoption particularly in low and middle-income countries. The average cost in the U.S. is approximately $3,839.60 (OEM price) for pumps and $1,067.00 for consumables. Footnotes Fortune Business Insights - Insulin Pump Market Size, Share, Growth | Global Report [2032] https://www.fortunebusinessinsights.com/insulin-pump-market-102735